Takeda Pharmaceutical Co. has announced that Ninlaro (ixazomib), combined with lenalidomide and dexamethasone as a therapeutic approach for relapsed and/or refractory multiple myeloma (MM), markedly increases a patient’s progression free survival, according to the results of a Phase 3 clinical trial, published as “Oral Ixazomib, Lenalidomide, and…
A new class of drugs that activate a protein in cells’ endoplasmic reticulum may be used as an adjuvant therapy to treat B-cell malignancies, according to the study “Agonist-mediated activation of STING induces apoptosis in malignant B cells,” published in Cancer Research. The cellular endoplasmic reticulum…
The International Myeloma Foundation (IMF) has announced new funding for the first comprehensive screening study that aims to prevent myeloma before it develops. The funded study, titled “iStopMM (Iceland Screens Treats or Prevents Multiple Myeloma),” will examine blood samples from 140,000 people in Iceland over the age of 40, seeking the earliest signs of the…
Advocates working to raise awareness and funds for multiple myeloma successfully climbed Mount Kilimanjaro, and a documentary about the climb premiered last month at the Eden Roc Miami. The group included 15 multiple myeloma patients, doctors, family members, and supporters. The climb took place in January and raised about $250,000 for the disease.
A screening study — the largest of its kind for myeloma — hopes to find a way to prevent myeloma before it develops. The study, called iStopMM (Iceland Screens Treats or Prevents Multiple Myeloma), was announced by the International Myeloma Foundation (IMF), which is funding the research. The organization is the largest…
Get regular updates to your inbox.